IDEAYA Biosciences, a company focused on cancer treatment development, has released its financial results for the third quarter of 2025, alongside an update on its ongoing business operations. A key highlight of the report centers on the progress of their Phase 2/3 clinical trial, OptimUM-02, which is evaluating the effectiveness of a drug combination – darovasertib and crizotinib – in treating a specific type of eye cancer called metastatic uveal melanoma (mUM).

This particular trial focuses on patients whose tumors are HLA*A2-negative, a genetic marker that indicates a specific subtype of mUM. The company anticipates announcing median Progression-Free Survival (PFS) data from the OptimUM-02 trial between the end of 2025 and the first quarter of 2026. PFS is a crucial measurement in cancer trials, indicating the length of time during and after treatment that a patient's cancer does not worsen.

Furthermore, IDEAYA Biosciences confirmed that they are on track to complete enrollment for the OptimUM-02 trial by the end of the year. Successfully completing enrollment is a significant milestone, ensuring the trial has a sufficient number of participants to generate statistically meaningful results.

The announcement also referenced previously reported data showcasing the potential of the darovasertib/crizotinib combination. Data indicated a median Overall Survival (OS) of 21.1 months and a median PFS of 7.0 months. Overall Survival refers to the average length of time patients in the study lived. These prior results offer a promising glimpse into the potential benefits of this treatment approach for patients with HLA*A2-negative metastatic uveal melanoma. The upcoming PFS data readout from the Phase 2/3 trial will be critical in further assessing the efficacy and safety of the darovasertib/crizotinib combination and informing future development plans. Investors and the medical community alike are eagerly awaiting these results, as new treatment options are urgently needed for this challenging cancer.